医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

R-Tech Ueno: Lawsuit Claiming Infringement of AMITIZA® Capsules Patents

2014年11月13日 AM10:57
このエントリーをはてなブックマークに追加


 

TOKYO

R-Tech Ueno (JASDAQ:4573):

Sucampo Pharmaceuticals, Inc. (“Sucampo”) announced that it, together with R-Tech Ueno, Ltd., Sucampo AG, and Takeda Pharmaceutical Company Limited (“Takeda”) and certain affiliates of Takeda, have filed a patent infringement lawsuit against Dr. Reddy’s Laboratories, Ltd. and Dr. Reddy’s Laboratories, Inc. (collectively, Dr. Reddy’s), which had filed Abbreviated New Drug Application (ANDA) with the U.S. Food and Drug Administration (FDA) to market a generic version of the 8 mcg and 24 mcg AMITIZA® (lubiprostone) oral capsules. (For more details, please refer to Sucampo’s release dated November 12, 2014)

As a result of Sucampo’s filing of the said lawsuit, final FDA approval of Dr. Reddy’s’s ANDA will be stayed up to 30 months from October 3, 2014.

The said filing will have no impact on the forecast of business results for the fiscal year ending March 2015.

For full details of the press release, please visit:
http://www.rtechueno.com/en/investor/press/documents/141113_pr_en.pdf

CONTACT

R-Tech Ueno, Ltd.
Koji Nakamura, +81-3-3596-8011
Director
Business
Management Department
info@rtueno.co.jp

Related Posts Plugin for WordPress, Blogger...
 

同じカテゴリーの記事 

  • P&G Sets New Goal to Deliver 25 Billion Liters of Clean Drinking Water to Families in Need Worldwide
  • Puma Biotechnology’s Licensing Partner Specialised Therapeutics Asia Receives Regulatory Approval to Commercialize NERLYNX® (neratinib) for Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer
  • Takeda Receives U.S. FDA Approval to Manufacture FLEXBUMIN® at New Plasma Manufacturing Facility near Covington, Georgia
  • オクタファルマ・グループが2018年の好業績を発表
  • 香港贸发局香港国际医疗及保健展尖端医疗科技及保健产品 迎合采购所需